Long‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemia |
| |
Authors: | Edouard Cornet Cécile Tomowiak Aline Tanguy‐Schmidt Stéphane Lepretre Jehan Dupuis Pierre Feugier Alain Devidas Clara Mariette Véronique Leblond Catherine Thiéblemont Patricia Validire‐Charpy Laurent Sutton Emmanuel Gyan Jean‐Claude Eisenmann Pascale Cony‐Makhoul Loïc Ysebaert Xavier Troussard the Société Française d'Hématologie |
| |
Affiliation: | 1. Caen University Hospital, Laboratory of Haematology, , Caen, France;2. University of Caen, Medical School, EA4652, , Caen, France;3. Caen University Hospital, Regional Registry of Malignant Haemopathies of Lower‐Normandy, , Caen, France;4. Department of Oncology Haematology and Cell Therapy, Poitiers University Hospital, , Poitiers, France;5. Department of Haematology, Angers University Hospital, , Angers Cedex 9, France;6. Department of Haematology, Centre de lutte contre le cancer Henri Becquerel, , Rouen, France;7. Lymphoid haemopathy unit, Henri Mondor Hospital, , Créteil, France;8. Department of Haematology, Nancy University Hospital, , Vandoeuvre Lès Nancy, France;9. Department of Haematology, Sud Francilien Hospital, , Corbeil Essonnes, France;10. Department of Haematology, Grenoble University Hospital, , Grenoble, France;11. Department of Haematology, Pitié‐Salpétrière Hospital, , Paris Cedex 13, France;12. Department of Oncology Haematology, Saint‐Louis Hospital, , Paris Cedex 10, France;13. Department of Haematology, Curie Institute, , Saint‐Cloud, France;14. Department of Haematology, Victor Dupouy Hospital, , Argenteuil, France;15. Department of Haematology and Cell Therapy, Tours University Hospital, , Tours, France;16. Department of Haematology, Mulhouse Hospital, , Mulhouse, France;17. Clinical Research Centre, Annecy Hospital, , Pringy Cedex, France;18. Department of Haematology, Toulouse University Hospital, , Toulouse Cedex 9, France |
| |
Abstract: | A large, multicentre, retrospective survey of patients with hairy cell leukaemia (HCL) was conducted in France to determine the frequency of second malignancies and to analyse the long‐term effects of the established purine nucleoside analogues (PNAs), cladribine and pentostatin. The survey retrospectively reviewed the medical history of patients and their immediate family, clinical and biological presentation at the time of HCL diagnosis, treatment choice, response to treatment, time to relapse and cause of death. Data were collected for 487 patients with HCL. Of the patients included in the survey, 18% (88/487) had a familial history of cancers, 8% (41/487) presented with malignancies before HCL diagnosis and 10% (48/487) developed second malignancies after HCL was diagnosed. An excess incidence of second malignancies was observed, with a standardized incidence ratio (SIR) of 1·86 (95% confidence interval (CI): 1·34–2·51), with no significant difference between PNAs. For second haematological malignancies alone, the SIR was markedly increased at 5·32 (95% CI: 2·90–8·92). This study highlights the high frequency of cancers in HCL patients and their family members. The frequency of second malignancies is notably increased, particularly for haematological malignancies. The respective role of pentostatin and cladribine in the development of second malignancies is debatable. |
| |
Keywords: | hairy cell leukaemia purine nucleoside analogues second malignancies |
|
|